The White House likely is concerned about the potential precedent from a provision in the House bill that would link FDA funding to release of guidance. OMB says it opposes provisions that “unduly interfere” with the FDA rulemaking process.
The Obama administration took the rare step of including an objection to an FDA-related provision in its threat to veto a House fiscal 2015 appropriations bill.
The White House Office of Management and Budget, in a June 10 Statement of Administration Policy, included the House provision withholding $20 million from FDA until the agency...
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.
Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.
